Audience
Healthcare panel (US)
Healthcare (US): a public Ask Brox audience of Brox clones, each built from a long-form interview with a real person. Every insight fielded on this panel, newest first.
What did the Healthcare panel say?
- #
48.5%
48.5% would stop the blood pressure pill once its copay rose from $15 to $60 a month, on top of no felt benefit and afternoon tiredness, up from 14.0% with the tiredness alone and 1.5% with no felt benefit alone. — Patient adherence breaks at the copay: 48.5% would stop a daily blood pressure pill when it jumps from $15 to $60 a month
base 200
- #
35%
35.0% would stay on an antidepressant that is helping at $150 a month, against 82.2% at $50 and 97.0% at $10; no clone rates itself more likely to stay on at a higher price. — Antidepressant cost: only 35.0% of US adults prescribed one for depression would stay on it at $150 a month, against 82.2% at $50
base 197
- #
56.5%
56.5% of health plan members (113 of 200) say what they pay at the pharmacy for each prescription is the part of their drug coverage that matters most, 41.0% (82) say whether their medicines are covered at all, and 1.5% (3) say using the pharmacy they want near home. — Health plan pharmacy benefits: 56.5% of members judge them on the price per prescription, and 73.5% would give up their local pharmacy for mail delivery to save $5 a month
base 200
- #
73.5%
73.5% would switch health plans at open enrollment if a medicine they take every month moved to a higher cost tier and cost $75 a month more, against 24.0% at $25 a month more and 96.0% at $200: the same 200 clones, three times as many between $25 and $75. — Health plan formulary changes: 24% would switch plans if a monthly medicine cost $25 more, 73.5% at $75, but 94% would ask their doctor first if it were dropped
base 200
What has Brox published on healthcare panel (us)?Newest first
-
Patient adherence breaks at the copay: 48.5% would stop a daily blood pressure pill when it jumps from $15 to $60 a month
48.5% 48.5% would stop the blood pressure pill once its copay rose from $15 to $60 a month, on top of no felt benefit and afternoon tiredness, up from 14.0% with the tiredness alone and 1.5% with no felt benefit alone. (base 200)
Read -
Antidepressant cost: only 35.0% of US adults prescribed one for depression would stay on it at $150 a month, against 82.2% at $50
35% 35.0% would stay on an antidepressant that is helping at $150 a month, against 82.2% at $50 and 97.0% at $10; no clone rates itself more likely to stay on at a higher price. (base 197)
Read -
Health plan pharmacy benefits: 56.5% of members judge them on the price per prescription, and 73.5% would give up their local pharmacy for mail delivery to save $5 a month
56.5% 56.5% of health plan members (113 of 200) say what they pay at the pharmacy for each prescription is the part of their drug coverage that matters most, 41.0% (82) say whether their medicines are covered at all, and 1.5% (3) say using the pharmacy they want near home. (base 200)
Read -
Health plan formulary changes: 24% would switch plans if a monthly medicine cost $25 more, 73.5% at $75, but 94% would ask their doctor first if it were dropped
73.5% 73.5% would switch health plans at open enrollment if a medicine they take every month moved to a higher cost tier and cost $75 a month more, against 24.0% at $25 a month more and 96.0% at $200: the same 200 clones, three times as many between $25 and $75. (base 200)
Read -
Health plan switching at open enrollment: 47% would leave if their doctor left the network, 7.5% for a $40 a month premium increase
47% 47.0% would switch health plans at open enrollment if their main doctor left the plan’s network with the premium unchanged, against 7.5% for a $40 a month premium increase with nothing else changed: the same 200 clones, six times as many moved by the network. (base 200)
Read -
Side-effect fears hold back 67.0% of US adults from a recommended statin, and a test of their own heart risk, not a lower price, is what would change their minds
67% 67.0% say worry about side effects would most hold them back from starting a statin their doctor recommends while they feel well; 19.5% would rather try diet and exercise first and 2.5% name the monthly cost. (base 200)
Read -
Cash to go ahead with a delayed $3,000 treatment: no US adult would for under $1,000, and 97 of 200 would need the full $3,000
0 There is no cheap nudge. Not one person in 200 would proceed for less than $1,000. (base 200)
Read -
When a pharmacy closes, 89% would stay with the same chain, and an on-time guarantee holds them better than a discount
89% A store closing moves almost nobody off the chain: 89% (178 of 200) would keep their prescriptions with it. (base 200)
Read -
Medicare Advantage members would stay for their doctors, not a lower price: 12 of 23 name keeping their providers
12 For the Medicare Advantage members on this panel, keeping their own doctors is the one thing that would hold them to their insurer. (base 23)
Read -
Fear of side effects, not cost, keeps 53.6% of US migraine sufferers on the treatment they have
53.6% 53.6% of US migraine sufferers say worry about the side effects of something new is what would most keep them on their current treatment if a new one were available; 31.8% say what they have works well enough, 6.4% say their doctor has not suggested changing, 4.5% would switch as soon as something better appeared and 3.6% are unsure what a new drug would cost or whether insurance would cover it. (base 110)
Read
What do people ask about healthcare panel (us)?
- Why do patients stop taking a daily medicine after the first few months, and what would keep them on it?
- 48.5% of US adults who take a daily prescription medicine (n=200, November 2026) would stop a new blood pressure pill once its copay rose from $15 to $60 a month on top of no felt benefit and afternoon tiredness, against 14.0% before the copay rise and 1.5% with no side effect at all.Read the insight
- How do health plan members judge their plan's pharmacy benefit, and which part of it matters most?
- 56.5% of US health plan members on employer, marketplace or Medicare coverage say what they pay at the pharmacy per prescription matters most in their drug coverage and 41.0% say whether their medicines are covered, against 1.5% for using the pharmacy they want (n=200, November 2026).Read the insight
- Why do US adults with depression stop an antidepressant, and what would have kept them on it?
- Cost and side effects: 82.2% of US adults prescribed an antidepressant for depression would stay on one that helps at $50 a month but 35.0% at $150, and 51.3% say a quick switch when side effects bother them would keep them on it (n=197, November 2026).Read the insight
- Why do members leave a health plan after a formulary change drops or re-tiers a medicine they take?
- Told a medicine they take every month was moving to a higher cost tier, 24.0% of 200 US health plan members on employer, marketplace or Medicare coverage would switch plans at their next open enrollment if their share rose by $25 a month, against 73.5% at $75 a month (n=200, November 2026).Read the insight
- What makes a health plan member switch plans at open enrollment, and what keeps them?
- Told their main doctor would leave their health plan’s network with the premium unchanged, 47.0% of 200 US adults on employer, marketplace or Medicare coverage would switch plans at open enrollment, against 7.5% for a $40 a month premium increase with nothing else changed (n=200, November 2026).Read the insight
- What stops patients starting a preventive medicine their doctor has recommended?
- Worry about side effects is the main thing that would stop 67.0% of US adults starting a daily statin their doctor recommends while they feel well (n=200, October 2026), while 62.5% say a test showing their own heart risk is high would most persuade them to start, against 1.0% who name a lower price.Read the insight
- When a health plan deductible leaves a needed treatment costing about $3,000 out of pocket, how large does a cash payment have to be before people go ahead with it, and does it matter whether the money arrives before or after the treatment?
- Not one of 200 US adults would go ahead with a $3,000 treatment they had been putting off for a cash payment under $1,000, and 97 of the 200 need the full $3,000 back, September 2026.Read the insight
- Where do people move their prescriptions when the pharmacy store filling them closes, and what would keep them with the same chain?
- 89% of US pharmacy users (178 of 200) would keep their prescriptions with the same chain when their store closes, and a guarantee the prescription is ready on time is the strongest thing that holds them (75.5%), while a discount is the weakest (36.5%), September 2026.Read the insight
- Where do Medicare Advantage members go when their plan is discontinued, and what would hold them?
- Asked what would most keep them with their insurer if their plan ended, 12 of 23 US Medicare Advantage members on the panel named keeping their own doctors and 2 named lower costs, September 2026.Read the insight
- How do migraine sufferers decide between a new preventive and staying on what they have?
- Worry about a new drug's side effects is what would most keep 53.6% of US migraine sufferers on their current treatment, against 31.8% who say what they have works well enough (n=110, September 2026), and a covered once-daily pill that halves migraine days at no extra cost moved only 12.7% to try it.Read the insight
Other audiences
- Anime Fans (US) 4
- Brox HNWI (US) 8
- Casual dining and restaurants (US) 2
- E-commerce (US) 7
- Finance (US) 5
- G.B. nat. rep. (GB) 14
- GLP-1 (US) 1
- GLP-1 Considerers (US) 2
- GLP-1 Past Users (US) 3
- Groceries (US) 3
- HCP (US) 10
- HCP Dermatologists (US) 4
- HCP Other (Non-Derm) (US) 2
- Healthcare Professionals (US) 1
- HNWI (VC/Tech) (US) 3
- Insurance (US) 15
- Investing (US) 1
- Japan nat. rep. (JP) 1
- Music (US) 1
- Streaming (JP) 1
- Streaming (US) 16
- Streaming (TR) 1
- Streaming - Custom (US) 2
- Tech (US) 5
- Tech (GB) 1
- Travel (US) 6
- TV & Social Media (JP) 1
- U.S. nat. rep. (US) 102
How should you read these findings?
Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.
Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.
What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.
Ask this of your own customers: humans@brox.ai